Quantisnow Logo
Dashboard

SEC Form EFFECT filed by Five Prime Therapeutics, Inc.

$FPRX
Major Pharmaceuticals
Health Care
Get the next $FPRX alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $FPRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FPRX

DatePrice TargetRatingAnalyst
More analyst ratings

$FPRX
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

    SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

    $FACT
    $FPRX
    $PDLI
    Major Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

  • Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

    THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. "Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 tr

    $FPRX
    $AMGN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

  • Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The cancellation is the result of the company’s announcement on March 4, 2021 that it has entered into an agreement under which Amgen Inc. will acquire Five Prime Therapeutics. Five Prime will issue its fourth quarter and full-year 2020 financial results in its Form 10-K that it will file with the Securities and Exchange Commission. About Five Prime Therapeutics Five Prime is a clinical stage biotech

    $FPRX
    Major Pharmaceuticals
    Health Care

$FPRX
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FPRX
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FPRX
 SEC Filings

See more

$FPRX
 Leadership Updates

Live Leadership Updates

See more

  • Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

    SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut

    $FACT
    $FPRX
    $PDLI
    Major Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$FPRX
 Financials

Live finance-specific insights

See more

  • Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

    THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses. "Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 tr

    $FPRX
    $AMGN
    Major Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$FPRX
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more